To understand the molecular mechanism of rectal cancer and develop markers for disease prognostication, we generated and explored a dataset from 243 rectal cancer patients by gene expression microarray analysis of cancer samples and matched controls, and SNP-arrays of germline DNA. We found that two of the loci most strongly linked with colorectal cancer (CRC) risk, 8q24 (upstream of MYC) and 18q21 (in the intron of SMAD7), as well as 20q13 (in the intron of LAMA5), are tightly associated with the prognosis of rectal cancer patients. For SNPs on 18q21 (rs12953717 and rs4464148) and 20q13 (rs4925386), alleles that correlate with higher risk for the development of CRC are associated with shorter disease free survival (DFS). However, for rs6983267 on 8q24, the low risk allele is associated with a higher risk for recurrence and metastasis after surgery, and importantly, is strongly correlated with the resistance of CRC cell lines to chemoradiotherapy (CRT). We also found that although MYC expression is dramatically increased in cancer, patients with higher levels of MYC have a better prognosis. The expression of SMAD7 is weakly correlated with DFS. Notably, the presence of the 8q24 and 18q21 SNP alleles is not correlated with expression levels of MYC and SMAD7. rs4464148, and probably rs6983267 and rs4925386, are linked with overall survival time of patients. In conclusion, we show that several CRC risk SNPs detect subpopulations of rectal cancer patients with poor prognosis, and that rs6983267 probably affects prognosis through interfering with the resistance of cancer cells to CRT. wileyonlinelibrary.com/journal/gcc
| I N TR ODU C TI ON
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death in the USA. Each year there are more than 130,000 new cases and more than 49,000 deaths from CRC. 1 Rectal cancers account for some 35% of all CRC cases. 2 Despite similarities in the genetic aberrations profiles rectal cancer and colon cancer from microsatellite stable (MSS) patients show significant differences in clinical outcome. Anatomic differences also influence the treatment of these cancers. While colon cancers are usually surgically removed and then treated with adjuvant chemotherapy, the standard treatment for locally advanced rectal cancers consists of a preoperative chemoradiotherapy (CRT) 3, 4 followed by a total mesorectal excision of the tumor. Furthermore, the typical site of metastasis or progression is different: colon cancers metastasize primarily to liver and have a tendency to spread to the peritoneum, while distal rectal cancers often surpass the liver and spread to the lung. 5 Molecular and genetic studies as well reveal both remarkable similarities but also some noteworthy distinctions. For example, APC mutations occur with higher frequency in rectal cancer than in colon cancer. 6, 7 Many genome-wide association studies (GWAS) have successfully identified more than 20 SNPs associated with the risk for the development of CRC. 8, 9 As outlined above, colon and rectal cancers are very different in their clinical behavior. To our knowledge, the prognostic value of these SNPs has not been systematically evaluated in rectal cancer patients. Here, we analyze an extensive dataset of rectal cancers to identify if any of these SNPs are also associated with outcome in rectal cancer patients. SNPs associated with prognosis might augment already established clinical tests and could help to individualize a patients' treatment.
The most extensively studied risk locus of cancer is the SNP rs6983267 on chromosome band 8q24. The G allele of rs6983267 increases the risk of developing several cancers, including CRC, prostate cancer and breast cancer. 10, 11 Several hypotheses have been proposed to explain the effect of rs6983267, including enhanced binding of the WNT pathway transcription factor TCF7L2 in the MYC promoter region, hence activating transcription. 12, 13 Another possible mechanism of action might be interference with the expression of the noncoding RNA CCAT2 and CARLo-5. 14, 15 The second most studied risk locus on 18q21 contains three SNPs: rs4939827, rs12953717 and rs4464148.
They map to introns of the tumor suppressor gene SMAD7, 16, 17 influencing its expression. SMAD7 is involved in the regulation of the TGFb pathway. 18 In this study, we explore whether the SNPs that affect the risk of the development of CRC also alter the prognosis of rectal cancer patients and whether their presence affects the expression of adjacent genes.
| M A TE RI A L S A ND M E TH ODS

| Patients
Overall, 243 patients were included in this analysis. 230 patients could be included in the survival analysis (Supplementary Information, Table   S1 ). All patients were staged as locally advanced (cUICCII/III/IV) and treated according to the CAO/ARO/AIO-94 4 or the CAO/ARO/AIO-04 trial. 19 Staging included rigid rectoscopy and endorectal ultrasonography, magnetic resonance imaging (MRI) and/or computed tomography as well as patho-histological diagnosis of an adenocarcinoma.
Preoperative staging was performed as clinically assessed T-level (T), lymph node status (N) and distant metastases (M). The results were unified as clinical UICC stage (UICC). 
| Tumor biopsies, RNA/DNA isolation
During rectoscopy several biopsies of tumor and matched normal mucosa were taken in addition to the diagnostic sample, as well as EDTA-blood as previously described. 21 For gene expression analyses biopsies were immediately stored in RNAlater and kept at 48C over night. The following day biopsies were frozen and stored at 2208C.
Blood was centrifuged (2200 rpm, 10 min at 48C), plasma and the cellular components (leukocyte phase) were aliquoted and stored at 2808C.
Using TRIZOL (Life Technologies, Rockville, MD, USA) RNA was extracted from RNAlater biopsies as previously described. 22 All samples underwent strict quality assessment. Nucleic acid quantity and purity were determined using the NanoDrop spectrophotometer ND1000 were assessed using Nanodrop and Bioanalyzer.
| Gene expression microarray analysis
Microarrays analysis was performed as previously described. 22 Briefly, Table S1 ).
The Bioconductor package arrayQualityMetrics was used to determine the quality of microarray data. The signal intensities from the gene expression arrays were log2 transformed before being normalized to the 75 percentile as instructed by the Agilent protocol. Probes with maximum intensity over all samples of at least 100 were used for further analysis. Gene fold change of each cancer sample was calculated with paired normal mucosa sample as reference if available, otherwise the geometric average intensity of all normal samples was used as ref-
erence. Gene expression data were deposited to Gene Expression Omnibus (GSE87211). A change of gene expression with a threshold of 3-fold change (either up or down) and a P value of 0.05 in two tailed unpaired t-test after multiple test correction was considered to be significant. The list of genes, the expression of which significantly differed between the cancer and the mucosa control, was used for Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Germany) in Supplementary Information, Table S2 using the standard methods. The false discovery rate is the adjusted P value with Benjamini-Hochberg method. Survival data were evaluated using the univariate and multivariate Cox proportional hazards model. Only variables with a significant value of P < 0.05 in univariate analysis were used in the construction of subsequent multivariate Cox models. Cox P value is used unless otherwise stated. Samples were separated into two groups of equal size for high and low gene expression.
| Illumina infinium HD assay
PCA (Principal
The SNPs tested in this study influence CRC occurrence at very different strengths. [23] [24] [25] From biological intuition, a factor's ability to increase CRC risk is likely to be correlated to its potential effect on recurrence risk, and such an inequality will invalidate the assumption of multiple test correction. This inequality can be revealed by enrichment analysis. Among 3 loci with significant effect on rectal cancer recurrence, two are localized on the no.1 and no.3 locus with highest CRC risk in the total list of 21 loci. The biased distribution P < 0.028 confirmed the significant association between CRC risk and recurrence risk. With this confirmed inequality, multiple test correction was not applied for SNP number in this study. that do not harbor KRAS mutations benefit from anti-EGFR therapy. 26 Our data show that the KRAS mutation status cannot predict response to neoadjuvant chemoradiotherapy ( Table 2 , Supplementary Information, Figure S1E and J).
| Association of polymorphisms and interval to recurrence after surgery
Many GWAS of CRC have identified polymorphisms in at least 22 loci associated with an increased risk of developing CRC. We investigated the association of 21 of those loci with DSF and OS. We found three loci that are significantly associated with rectal cancer recurrence, including rs6983267 on 8q24 upstream of MYC, rs12953717 and rs4464148 on 18q21 in an intron of SMAD7, and rs4925386 on 20q13
in an intron of LAMA5 (Table 1 ). The SNP rs4464148 on 18q21 also has a significant effect on OS, while the SNP rs6983267 on 8q24 (P 5 0.076) and the SNP rs4925386 on 20q13 (P 5 0.053) have noticeable effect although not significant (Table 1 ). 8q24 and 18q21 are among the loci with the most significant P value for CRC risk ( Table   1) . 27 Interestingly, rs6983267 has opposite effects when analyzed for CRC susceptibility and prognosis. The high-risk allele G of rs6983267
correlates with an increase in CRC incidence in the population, but is associated with a longer DSF and OS for rectal cancer patients when compared to the low-risk allele T (Table 1) . We have investigated the difference in sensitivity of CRC cell lines to CRT. 28 We found that the CRT sensitivities of CRC cell lines are tightly correlated with their rs6983267 genotypes. Cell lines with higher CRT resistance invariably carry the T allele that is associated with short DSF in rectal cancer patients ( Figure 2F ). Such an allelic specific distribution is not observed for any other significant SNPs ( Supplementary Information, Figure S2 ).
Allele G of rs6983267 enhances CRC incidence with a dosage effect;
this fits with an additive model, 29 while CRC recurrence of patients carrying the allele T fits best with a dominant model; thus, patients with the GT allele have survival curves very similar to the TT allele (DSF: HR 5 2.21, 95% CI 1.03-4.74, P 5 0.042) (Figure 2A ). In contrast, the high-risk alleles for CRC occurrence and recurrence are the same for rs12953717 and rs4464148 ( Table 1 (Table 2) .
After multiple test correction, we did not detect any significantly differentially expressed genes among samples with different rs6983267 genotypes (data not shown). However, we discovered that, under a loose criterion of t test P value < 0.05 with no correction for multiple testing, the expression of two radioresistance related genes, NOS1 and AATK, 30-32 is correlated with allele number and has a P 
| Association between prognosis and the expression of genes adjacent to SNPs associated with CRC
We examined the expression of genes potentially linked with the SNPs on 8q24, 18q21 and 20q13, which are MYC, SMAD7 and LAMA5, respectively. Our data show no correlation between their expression levels and the presence of specific SNPs ( Figure 3D-H) .
In addition, the overall expression levels of these genes with respect to different alleles for any of these SNPs are indistinguishable from each other (data not shown). But MYC, and to a lesser extent SMAD7, do have an association with prognosis. Compared to matched normal mucosa, rectal cancers have significantly higher expression of MYC and lower expression of SMAD7 ( Figure 3A and B). However, patients with lower MYC expression or higher SMAD7 expression have shorter DSF and probably shorter OS, though the P value is only significant for effect of MYC expression on DSF expression is consistently increased in cancer samples ( Figure 3C ), but it is not correlated with prognosis ( Figure 4C and F) . These results were confirmed with independent CRC sample sets (Supplementary Information, Figure S5 ).
| D I SCUSSION
Previous GWAS studies have identified dozens of loci associated with an increased risk for the development of CRC. 8, 9 In this study we determined whether those loci affect the prognosis of patients with rectal cancers, which comprise approximately 35% of patients with CRC. 2 We did observe that three loci, on chromosome bands 8q24, 18q21 and 20q13, significantly influence DSF, and to a lesser extent, OS. It is reasonable to assume that genetic factors that increase the risk for cancer development could also affect disease prognostication.
Consistently, we found that two out of these three loci (8q24 and 18q21) are among the loci with strongest association with CRC risk (significance rank no.1 and no.3 respectively in the GWAS study of Houlston 2008). 33 They are also the 1 st and 2 nd loci found associated with colorectal cancer. [24] [25] [26] Both loci are associated with highly significant P value in many GWAS 34 and are the two most extensively studies studied CRC risk loci.rs6983267 on 8q24 has been found to be strongly associated with multiple cancer types, including CRC, 10 prostate cancer, 35 and thyroid cancer. 11 Interestingly, 8q24 SNP rs6983267 has divergent effects on CRC occurrence and prognosis. This is reminiscent of the effect of BRCA1/2 mutations on breast cancer risk, which is significantly increased in women carrying these mutations. But they correlate with longer DSF and OS time in patients with triple negative breast cancers. 36 Such a reverse association of rs6983267 is also found in prostate cancer, where the G allele correlates with the risk of cancer occurrence, while the T allele is significantly associated with metastatic prostate cancer, with 1.49 risk ratio over the G allele. 37 The fact that Figure S3 ). This effect might also arise from allele-related differences in general expression response to CRT, which could be revealed by a future meta-analysis of post-CRT samples.
Rectal cancer samples have greatly increased expression levels of MYC compared to matched normal mucosa, while the expression of SMAD7 is consistently decreased; however, patients with higher MYC expression or lower SMAD7 expression show a better prognosis than patients with an opposite expression pattern (see below).
The SNPs on 18q21 locus also correlates with prognosis. But unlike rs6983267, the alleles on 18q21, rs4939827, rs12953717 and rs4464148 have the same effect on CRC risk and recurrence of patients with rectal cancer. These three SNPs are in the same intron of SMAD7 and are in high linkage disequilibrium. 29, 38 We found that the alleles of rs12953717 and rs4464148 are significantly associated with DSF. The 3 rd SNP, rs4939827, shows the same trend, although with an insignificant P value, likely due to the limited sample size ( Figure 2B , Table 1 ). Not surprisingly, the directions of the effects on DSF are the same as on OS for those SNPs affecting both DSF and OS (rs4464148, rs6983267 and rs4925386).
The three loci correlated with prognosis of rectal cancer patients are adjacent to MYC, SMAD7 and LAMA5, respectively. MYC is involved both in hematological malignancies and solid tumors, and is required for oncogenesis in a mouse model of CRC. 39, 40 MYC is also an important regulator of cancer stem cells. 41 Cancer stem cells are significantly more resistant to CRT than the bulk tumor and are thought to be responsible for cancer recurrence after therapy. 42 One conceivable mechanism is that the long-term effect of rs6983267 on MYC expression perturbs the stemness of cells and results in a differential response of cancer cells to CRT. We found that the majority of CRC cancer samples have dramatically higher expression of MYC (>80% samples with >2 fold increase and >50% with >4 fold increase Figure 3F ), probably due to aberrant Wnt/b-catenin signaling. 43 Surprisingly, again we found that the expression level of MYC is reversely correlated with tumor aggressiveness; patients with high MYC expression having a longer DSF after surgery. rs6983267 has been reported to enhance binding of the transcription factor TCF7L2 to the enhancer of MYC. 44, 45 One could hypothesize that rs6983267 exerts its effect on CRC by directly interfering with MYC expression level. However, the expression level of MYC in both mucosa and tumor tissues is not correlated with rs6983267 alleles (Figure 3A) , even when normalized to genomic copy numbers of this locus (data not shown). This result does not rule out the possibility that the presence of rs6983267 influences CRC risk via an alteration of MYC expression during a transient but important period of tumorigenesis, but this change, if it exists, is masked by other process at later stages of CRC that drastically increase MYC expression.
SMAD7 is involved in tumorigenesis and metastasis. 46, 47 The samples analyzed in the present data set show dramatically decreased levels of SMAD7 expression when compared to matched normal mucosa.
SMAD7 expression levels showed a weak correlation with prognosis ( Figure 3J , Supplementary Information, Figure S5B ). Intriguingly, patients with lower SMAD7 expression have a longer DSF. The result is consistent with the finding that loss of SMAD7 is associated with a favorable outcome for CRC patients, while amplification of SMAD7 worsens survival. 48 Therefore, for both MYC and SMAD7, the change in In summary, our results suggest that polymorphisms at specific SNPs on chromosome bands 8q24, 18q21 and 20q13 hold promise as clinically useful tools to predict therapy outcomes and long term follow-up of rectal cancer patients. It will be informative to study the correlation between these SNPs and other CRC prognostic factors and to study whether there exists a differential response to various treatments used in patients with CRC depending on the presence of distinct alleles. These studies will provide a deeper understanding of the molecular mechanisms underlying the idiosyncrasies of individual tumor behavior and disease outcome, and hopefully will help to develop evidence-based individualized treatments.
